Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients

Sanjay Kumar Mishra, Pradeep Kumar*, Srishti Khullar, Amrita Joshi, Alok Sati, Sonali Vinay Kumar, Deepesh Unni and Atul Kumar

Abstract

Background: The current standard treatment for neovascular age-related macular degeneration (nAMD) involves intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents. The aim of the present study was to compare the effectiveness and safety of two anti-VEGF drugs: brolucizumab and aflibercept, in treatment-naïve nAMD Indian patients over a period of 48 weeks.

Methods: A prospective, randomized, single-centre, single-blinded, two-arm comparative study was conducted between March 2021 and February 2022. Of the 114 patients, 56 received intravitreal injections of brolucizumab (6 mg/50 µL) while 58 received aflibercept (2 mg/50 µL). The patients received 03 initial loading doses at 4-week intervals of both the agents and then respective therapies were given as individualized pro re nata (PRN) regimen based on the signs of active macular neovascularization. The functional and anatomical outcomes measured were mean change in best-corrected visual acuity (BCVA, logMAR), central retinal thickness (CMT, µm), presence of intraretinal fluid, subretinal fluid or subretinal hyper-reflective material. Furthermore, the average number of additional injections required after the loading doses, the injection-free interval and safety of both the drugs were also assessed.

Results: Brolucizumab was found to be non-inferior to aflibercept in terms of mean change in BCVA (−0.13 ± 0.21 logMAR vs. −0.10 ± 0.15 logMAR) and reduction in CMT (−112.59 ± 81.23 µm vs. −86.38 ± 71.82 µm). The percentage of eyes with IRF and SHRM was comparable between both the groups while fewer eyes treated with brolucizumab indicated SRF presence than aflibercept after the loading doses. These beneficial effects of brolucizumab were observed with significant (p < 0.0001) lesser number of injections (1.8 ± 1.1 vs. 3.8 ± 1.5) from week 12 to week 48. Moreover, the probability of no injections after the loading doses was significantly higher with brolucizumab compared to aflibercept indicating prolonged injection-free intervals. The average ocular side effects were comparable in the two groups. One adverse event of severe vitritis requiring treatment with oral steroids occurred in Brolucizumab group, while no such event occurred in Aflibercept group.

Conclusion: The results of the present study suggest non-inferiority of brolucizumab PRN regimen to aflibercept PRN regimen in treatment naïve nAMD Indian patients while achieving longer inter-injection intervals.
Background

Neovascular age-related macular degeneration (nAMD) is a chronic degenerative eye disorder affecting the macular region of retina and leads to gradual vision loss. The disease is associated with the growth of abnormal blood vessels from the choroid in the usually avascular retinal regions, thus leading to choroidal neovascularization (CNV), also known as macular neovascularization (MNV) [1]. The disease accounts for the third leading cause of blindness (8.7%) globally. It is projected to affect 288 million people worldwide by 2040 as the aging population rises [2]. The prevalence of AMD is comparatively higher in western countries, predominantly European regions, than in India. But it adds to a significant visual concern owing to the large population base [3, 4]. There is a paucity of prevalence data of late-stage nAMD in India. Few population studies report it ranging from 0.11 to 1.2% [5–7]. Late-stage AMD is associated with poor prognosis in the elderly if left untreated [8].

Anti-vascular endothelial growth factor (anti-VEGF) therapies have been proven to be a milestone in nAMD treatment in the last 15 years [9]. Since then, several anti-VEGF agents have been used clinically to treat AMD. Conventional anti-VEGF agents available are Bevacizumab, Ranibizumab, Aflibercept, and Brolucizumab, with brolucizumab being the latest addition [10]. At present, ranibizumab and aflibercept serve as first-line agents for the treatment of nAMD. In addition, ranibizumab is FDA approved at a dosing interval of 4 weeks while aflibercept at 8 weeks after 3 loading doses for managing nAMD [9]. However, although found effective, these drugs have limitations, such as poor compliance, frequent dosing injections, and economic burden. Therefore, long-acting anti-VEGF agents that may prolong the dosing interval may help improve the efficacy and adherence [9, 11].

Brolucizumab, a humanized, single-chain antibody fragment against VEGF-A, was approved for the treatment of nAMD in 2019 by the United States Food and Drug Association (USFDA) [10, 12, 13]. The phase 3 trials evaluating brolucizumab (6 mg, q12w), HAWK, and HARRIER trials showed comparable best-corrected visual acuity (BCVA) gains with fixed q8w aflibercept therapy. Furthermore, a significant number of patients maintained the 12-week dosing interval without any substantial increase in the adverse event profile [14]. Thus, it offers a promising possibility of increasing the duration of hospital visits for patients with nAMD. However, most of the patient population in the HAWK and HARRIER trials were outside India. Since the AMD burden and treatment may suffer regional and genetic disparity [4, 15], studies indicating its efficacy and safety in the Indian population are imperative.

Thus, the objective of this study was to evaluate the efficacy, duration of injection intervals, and safety of brolucizumab in the Indian population compared to aflibercept.

Methods

Study design

The present study was a prospective, randomized, single-centre, single-blinded, two-arm comparative study assessing the efficacy of brolucizumab compared to aflibercept in treatment-naïve nAMD patients (Clinical trial registration of India number CTRI/2021/06/034415). The local Institutional Ethics Committee of Army Hospital Research & Referral, Delhi Cantt, approved the protocol (Approval number 135/2020, dated Dec 7, 2020). The trial was conducted compliant with the principles of the Declaration of Helsinki. Prior to recruitment in the study, written informed consent was obtained from all the participants. The study was carried out at Army Hospital Research & Referral, Delhi Cantt, a tertiary care centre in New Delhi, India.

Study participants

Consecutive patients of untreated active CNV due to nAMD visiting our centre were recruited between December 2020 and February 2021, with no prior history of receiving any approved treatment for nAMD. They were assessed for inclusion and exclusion criteria (Table 1). At screening, all patients underwent detailed visual assessment with measurement of BCVA and a complete ophthalmic examination including slit-lamp examination, intraocular pressure measurement, and dilated fundus examination. In addition, all patients underwent Optical Coherence Tomography (OCT) imaging (Cirrus 5000, Carl Zeiss Meditec, Germany) to confirm the presence of MNV, SRF, and IRF. Further, patients showing active MNV underwent fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) (FF-450, Carl Zeiss Meditec, Germany). The entire clinical evaluation and multimodal imaging interpretation were made by two experienced vitreoretinal
surgeons of our institute. All the demographic variables were collected at the baseline visit.

Randomization and treatment
The eyes of the nAMD patients were randomized 1:1 to either Group 1, which was brolucizumab arm (6 mg/50 µL, Pagenax, Novartis India Ltd, Mumbai, India) or Group 2, which was aflibercept arm (2 mg/50 µL, Eylea, Bayer, India) using randomization tables. The interventional treatment was provided as intravitreal (IVT) injections of the two drugs in the affected eyes under topical anaesthesia in aseptic conditions. The treatment regimen involved initial loading i.e., 3 loading doses, followed by individualized pro re nata (PRN) regimen. Further the treatment was provided based on the signs of active CNV upon OCT and BCVA assessment of each patient.

The interventional PRN treatment was initiated by administering the loading doses (brolucizumab and aflibercept) at weeks 0 (baseline), 4, and 8. Following these 03 four weekly doses, all patients were examined at 4-weekly intervals (week 12–48) for disease activity assessment by a masked investigator. All patients underwent BCVA measurement, clinical ophthalmic examination, and macular OCT evaluation at each visit.

At each visit, the patients meeting the retreatment criteria (Table 2) were given the additional respective injection at the same dose; Group 1 received IVT brolucizumab 6.0 mg, and Group 2 received aflibercept 2.0 mg. The patients were blinded to the provided treatment. Further, the masked investigator decided to re-inject at each visit based on the BCVA and OCT macula interpretation supplied by the vitreoretinal surgeons. The results were then analysed by a reading team that was blinded to the treatment administered to the patient.

Outcome measurements
The primary efficacy parameters were changes in BCVA and central macular thickness (CMT) at weeks 12 and 48. The BCVA measurements were conducted in both eyes at screening and every 4 weeks after that, using the logMAR (Logarithm of the Minimum Angle of Resolution) chart (I Chart HD, Appasamy Associates, Chennai, India). It was conducted by a team of certified optometrists masked to the study and reported up to the second unit decimal in logMAR. The CMT was measured using the Cirrus 5000 HD OCT in both eyes at screening and every 4 weeks after that. The tracking function was used

Table 1  Inclusion and exclusion criteria for participation in the study

| Inclusion criteria                                                                 |
|-----------------------------------------------------------------------------------|
| Age more than 50 years                                                             |
| Typical morphology of age-related macular degeneration (AMD)                       |
| Lesion affecting the central subfield (1 mm around the centre)                     |
| Active choroidal neovascularization comprising more than 50% of the total lesion area |
| Intraretinal or Subretinal Fluid in central subfield                               |
| Best-corrected visual acuity between 20/32 to 20/400                               |

| Exclusion criteria                                                                 |
|-----------------------------------------------------------------------------------|
| Any fibrosis or geographical atrophy of central subfield                          |
| Any intra or periocular infection or inflammation                                |
| If the patient had received any approved treatment for neovascular AMD other than micronutrient supplementation |
| Any concurrent intraocular disease like diabetic retinopathy                      |
| History of drug sensitivity/ allergic reactions to research interventions          |
| Stroke or myocardial infarction in the 90 days preceding to baseline visit         |

Table 2  Retreatment criteria for patients requiring additional respective injections (Brolucizumab or Aflibercept) at each visit

| Retreatment criteria                                                                 |
|-----------------------------------------------------------------------------------|
| BCVA decrease by 0.10 from BCVA gained at 12-week review or last visit             |
| OCT CMT increase by 75 µm from CMT attained at 12-week review                      |
| The appearance of new IRF spaces in central 1.5 mm, i.e. 750 µm from the foveal centre |
| The appearance of new SRF space in central 1.5 mm, i.e. 750 µm from the foveal centre |
| Increase in SRF height from the status achieved at 12-week review                  |

BCVA Best-corrected visual acuity, OCT Optical coherence tomography, CMT Central macular thickness, IRF intraaretinal fluid, SRF subretinal fluid
to measure maximum readings through the same central point at all visits. The CMT assessment was conducted by two vitreoretinal surgeons to ensure the accuracy of the findings. The secondary efficacy parameters involved the review of the presence or absence of IRF, SRF or sub-retinal hyper-reflective material (SHRM) in the study eye at each visit. Besides, the average number of injections required for both the drugs and the average injection-free interval were also assessed. The same OCT imaging system was used throughout the study period at each visit to maintain consistency.

Additionally, safety evaluations involved measuring ocular adverse events (AE) throughout the treatment period. The AE were scored as 0 (no adverse events), 1 (subconjunctival haemorrhage and pain not requiring oral analgesic), 2 (anterior chamber [AC] cells and flare less than or equal to two with no circumciliary congestion, or ocular pain requiring oral analgesic), 3 (AC cells and flare more than two, circumciliary congestion, vitritis grade 1, and patient not requiring oral steroids for management) and 4 (Hypopyon in AC, synechiae formation, vitritis more than grade 2, optic disc oedema/hyperaemia, retinal vascular sheathing/haemorrhages in retina in addition to pre-existing CNV).

Endpoints and statistical analysis
The study endpoints included BCVA change from baseline to week 12 and baseline to week 48, absolute values and mean reduction in CMT from baseline to week 48, status of IRF, SRF and SHRM up to week 48, the average number of injections required, average injection-free interval and incidence of any ocular AE.

The sample size for the two arms was calculated considering 80% power and significance level of 0.05 (5%), disease prevalence of 1.47%, mean change in brolucizumab arm in previous studies at 5.9 letters and aflibercept arm at 5.3 letters, standard deviation (SD) of 14.79 for both arms, the margin of 9 letters, and attrition of 10%.

The statistical analysis was performed using R software (version 4.1.2) for Windows. The numerical variables were summarized descriptively as mean, median, standard deviation, minimum and maximum using the number of subjects in each treatment group. Categorical variables were summarized using count and percentage. BCVA was measured using Snellen’s chart and converted into logMAR values in decimal units. As appropriate, the between-group comparisons for categorical variables were done using chi-square test or Fisher’s exact test. While the numerical variables were compared using paired t-test and two-sample t-test for within-group and between-group comparisons, respectively. Kaplan–Meier method was conducted for the survival analysis on the injection-free duration. The subjects who did not take any injection at 48 weeks were censored. The log-rank test was used to compare the overall injection-free duration between the two treatment arms. The interquartile range was also provided for the injection-free duration. p-values < 0.05 were considered statistically significant.

Results
Study participants
During the study period, March 2021–February 2022, a total of 155 patients were assessed for eligibility, and 120 were found to be eligible. These patients were enrolled and randomized to receive either brolucizumab or aflibercept treatment. (60 eyes in each group, Fig. 1). Of the 120 patients randomized to treatment, 06 patients were lost to follow-up (04 in brolucizumab and 02 in aflibercept arm). Thus, the final analysis population included 56 patients in the brolucizumab and 58 patients in the aflibercept arm.

The demographic and baseline characteristics of the patients were balanced between both arms, as depicted in Table 3. The baseline BCVA was 0.84 ± 0.32 and 0.87 ± 0.27 in the brolucizumab and aflibercept arms, respectively. The absolute CMT values were balanced among both the arms (355.0 ± 89.7 in the brolucizumab arm and 365.5 ± 55.8 in the aflibercept arm). At baseline, IRF was present in 82.1% and 75.9%, SRF in 82.1% and 82.8%, while SHRM in 42.9% and 53.4% of patients in brolucizumab and aflibercept arm, respectively.

Efficacy parameters
The significant mean BCVA change was observed in both brolucizumab and aflibercept arms, respectively, from baseline to week 12 and from baseline to week 48. The mean change in logMAR BCVA from baseline to week 48 was −0.13 ± 0.21 for brolucizumab, and −0.10 ± 0.15 for aflibercept, respectively, with a difference of 0.03 [80% confidence interval (CI), −0.04 to 0.10] between the arms. At week 12, the mean change in logMAR BCVA from baseline was −0.18 ± 0.2 and −0.17 ± 0.15 for the brolucizumab and aflibercept arm. The mean change in logMAR BCVA at week 12 (p = 0.81) and 48 (p = 0.37) was found to be non-significant among both the groups. Further, these results indicated significant visual gains in BCVA for brolucizumab (p < 0.0001) as well as aflibercept (p < 0.0001). Figure 2A depicts the mean logMAR estimates for BCVA from baseline (week 0) to week 48. These results demonstrate that efficacy of brolucizumab is similar to aflibercept at weeks 12 and 48 without any statistically significant difference in BCVA.

The mean estimates for CMT from baseline (week 0) to week 48 are presented in Fig. 2B. The primary end-point of mean CMT change from week 0 to week 48 was −112.59 ± 81.23 µm and −86.38 ± 71.82 µm for
brolucizumab and aflibercept, respectively with a difference of $-26.21$ (80% CI, $-2.89$ to $55.31$). At week 12, the same was observed to be $-97.34 \pm 84.13 \, \mu m$ and $-84.34 \pm 71.51 \, \mu m$, respectively. There was no significant difference observed between the two groups at week 12 as well as week 48, which indicates non-inferiority of brolucizumab compared to aflibercept. Also, there was a significant reduction in CMT from baseline to week 48 in both groups ($p < 0.0001$). These results in Fig. 2B demonstrate that efficacy of brolucizumab is similar to aflibercept at weeks 12 and 48 without any statistically significant difference in CMT.

Figure 3 depicts the analysis of the presence or absence of IRF, SRF and SHRM in eyes treated with brolucizumab and aflibercept throughout the study period. The percentage of eyes with IRF for brolucizumab and aflibercept arm, respectively, at week 12 was 41.1% and 34.5% ($p=0.59$) and at week 48 was 50.0% and 67.3% ($p=0.10$), indicating non-inferiority of brolucizumab (Fig. 3A). Furthermore, the percentage of eyes with SRF for brolucizumab and aflibercept arm, respectively, at week 12 was 16.1% and 41.4% ($p=0.006$) and at week 48 was 9.3% and 38.2% ($p=0.0009$), indicating a significant beneficial effect of brolucizumab compared to aflibercept (Fig. 3B). Further, at week 12, SHRM was observed in 46.4% and 39.7% ($p=0.59$) of patients treated with brolucizumab and aflibercept, respectively, which was 64.8% and 69.1% at week 48 ($p=0.79$) (Fig. 3C). This indicated no significant differences between both the groups.

Furthermore, the mean number of injections required from week 12 to week 48 after the 3 loading doses in the brolucizumab arm was $1.8 \pm 1.1$ injections which were...
significantly less (p < 0.0001) compared to the aflibercept arm (3.8 ± 1.5 injections). The injection-free duration was computed for both treatments. The survival analysis was conducted to compare the probability of no injection between the two treatments, viz., brolucizumab and aflibercept. The median probability of no injection for brolucizumab was observed to be 2.9 (2.9, 5.7) weeks, while that of aflibercept was 1.4 (1.4, 1.9) weeks. The Kaplan–Meier curve for the probability of no injections was found to be significantly different (p < 0.01) between the two arms (Fig. 4), indicating that long dosing intervals were achieved successfully with brolucizumab. Table 4 shows the distribution of patients according to the additional injections required from week 12 to week 48.

The number of injections in Brolucizumab arm after week 8 was 94, compared to 180 in Aflibercept arm. The percentage of injections administered at an interval of 4 weeks, 8 weeks, 12 weeks, 16 weeks and 18 weeks was 17%, 7.5%, 19.2%, 24.5% and 13.8% in Brolucizumab group compared to 43.9%, 21.7%, 20.6%, 7.2% and 5% in Aflibercept group. Five patients in Brolucizumab group never received another injection after week 8 compared to one patient in Aflibercept group.

The frequency of AE improved significantly from baseline (62.5% in brolucizumab and 58.6% in aflibercept arm) to week 48 with 7.4% and 30.9% in the brolucizumab and aflibercept arm, respectively (Fig. 5). Overall, brolucizumab was well tolerated with limited ocular AE. Further, the frequency of AE was significantly less in brolucizumab arm than aflibercept arm at week 16 (p < 0.0001), 20 (p = 0.016) and 48 (p = 0.003) (Fig. 5). Table 6 represents the total mean scores of the AE per injection observed in each group at each visit. The mean side effect score per injection was significantly lower (p = 0.002) in the brolucizumab arm (0.07 ± 0.26) compared to the aflibercept arm (0.31 ± 0.47) at week 48 (Table 6). The most common AE was subconjunctival haemorrhage. Other observed ocular AE included presence of AC cells and flare, circumciliary congestion and one instance of severe vitritis. No presence of hypopyon in AC, synechiae formation, optic disc oedema/hyperaemia, retinal

### Table 3 The demographics and baseline characteristics of the patients

| Characteristics                  | Brolucizumab N = 56 | Aflibercept N = 58 | P value |
|----------------------------------|----------------------|--------------------|---------|
| Age, years                       |                      |                    |         |
| Mean ± SD                        | 72.05 ± 11.03        | 70.17 ± 9.02       | 0.32    |
| Median                          | 72.00                | 70.5               |         |
| Min, max                         | 51.00, 91.00         | 54.00, 91.00       |         |
| Sex, n (%)                       |                      |                    | 0.17    |
| Male                             | 37 (66.1)            | 30 (51.7)          |         |
| Female                           | 19 (33.9)            | 28 (48.3)          |         |
| LogMAR BCVA                      |                      |                    |         |
| Mean ± SD                        | 0.84 ± 0.32          | 0.87 ± 0.27        | 0.63    |
| Median                          | 0.28, 1.42           | 0.26, 1.30         |         |
| CMT (µm)                         |                      |                    |         |
| Mean ± SD                        | 355 ± 89.7           | 365.5 ± 55.78      | 0.46    |
| Median                          | 211.00, 598.00       | 265.00, 566.00     |         |
| Presence of IRF n (%)            | 46 (82.1)            | 44 (75.9)          | 0.55    |
| Presence of SRF n (%)            | 46 (82.1)            | 48 (82.8)          | > 0.99  |
| Presence of SHRM n (%)           | 24 (42.9)            | 31 (53.4)          | 0.35    |

Data presented as mean ± standard deviation or n (%)

BCVA: Best corrected visual acuity, CMT: Central macular thickness, IRF: intraretinal fluid, SRF: subretinal fluid, SHRM: subretinal hyper-reflective material, SD: standard deviation

* p-value < 0.05 for the t-test considered significant (none of the t-test found significance)

* p-values < 0.05 for the chi-square test considered for significant correlation (none of the chi-square test found correlation)

(See figure on next page.)

**Fig. 2** A The mean LogMAR BCVA values from baseline visit to week 48 visit for the patients treated with brolucizumab and aflibercept. B The mean CMT values from baseline to week 48 for the patients treated with brolucizumab and aflibercept.
Fig. 2 (See legend on previous page.)
Fig. 3  A Proportion of patients with presence of intraretinal fluid from baseline visit to week 48 visit. B Proportion of patients with presence of subretinal fluid from baseline visit to week 48 visit. C Proportion of patients with presence of subretinal hyperreflective material from baseline visit to week 48 visit.

Data presented as n (%). # - p-values <0.05 for the chi-square test considered for significant correlation.
The study participants who had received a loading dose of brolucizumab (6 mg/50µL) and aflibercept (2 mg/50µL) were treated as needed later and followed up for 48 weeks. The duration from the third injection to the administration of any additional injection (event) or to the final visit (loss to follow-up) was reported on daily basis. A log-rank test revealed that the curves for both the treatment arms (brolucizumab and aflibercept) were significantly different from each other (p<0.01). Brolucizumab showed longer injection free durations.

p-values <0.05 was considered for significantly different

Fig. 4 Kaplan–Meier curve for injection-free duration after the loading doses of brolucizumab and aflibercept

| Treatment  | Between 12 and 16 weeks | Between 20 and 24 weeks | Between 28 and 32 weeks | Between 36 and 40 weeks | Between 44 and 48 weeks |
|------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Brolucizumab (n = 56) | 3 (5.4%) | 17 (30.4%) | 3 (5.4%) | 1 (1.8%) | 2 (3.6%) |
| Aflibercept (n = 58) | 23 (39.7%) | 21 (36.2%) | 13 (22.4%) | 12 (20.7%) | 8 (13.8%) |
Table 5 The frequency of patients achieving different inter-injection intervals after receiving the third loading dose at week 8 in the two groups

| Treatment          | Interval of 4 weeks from last injection | Interval of 8 weeks from last injection | Interval of 12 weeks from last injection | Interval of 16 weeks from last injection | Interval of 20 weeks from last injection | Interval of 24 weeks from last injection | Interval of 28 weeks from last injection | Interval of 32 weeks from last injection | Interval of 36 weeks from last injection | NO injection after week 8 |
|--------------------|----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|----------------------------------------|
| Brolucizumab       | 16                                     | 7                                       | 18                                      | 23                                      | 13                                      | 11                                      | 4                                        | 1                                        | 1                                       | 5                                       |
| (94 injections after week 8) |                                        |                                          |                                          |                                          |                                          |                                          |                                          |                                          |                                          |                                        |
| Afibercept        | 79                                     | 39                                      | 37                                      | 13                                      | 9                                       | 2                                       | 1                                        | 0                                        | 0                                       | 1                                       |
| (180 injections after week 8) |                                        |                                          |                                          |                                          |                                          |                                          |                                          |                                          |                                          |                                        |
vascular sheathing or haemorrhages in the retina in addition to pre-existing MNV were noted during the study. No deaths were observed in any of the treatment arms. Also, none of the patients in both arms discontinued the treatment owing to AEs.

Only one patient in Brolucizumab group showed severe vitritis requiring treatment with oral steroids while no such event occurred in Aflibercept group. This patient had previously received 05 doses of Brolucizumab at 0, 4, 8, 16 and 28 weeks and developed this vitritis after the sixth dose of Brolucizumab at 40th week. The patient responded to treatment within two weeks and BCVA improved from 0.98 at week 40 (pre-injection) to 0.88 at week 48. The adverse events score during the entire study is highlighted in Table 7. Though the number of AEs is more in Aflibercept group, it is primarily due to a greater number of Aflibercept injections given after week 8 (180 injections) compared to Brolucizumab group (94 injections). The serious AEs (score 3 & 4) were more in Brolucizumab group. However it is pertinent to mention that the score 3 AEs responded to topical drugs alone and continued receiving further treatment with Brolucizumab during the study.

**Discussion**

The HAWK and HARRIER phase 3 trials have shown the non-inferiority of brolucizumab against aflibercept, with more than 50% of patients with nAMD maintaining the BCVA gains on q12w dosing interval throughout the study period of 48–96 weeks [14, 15]. In addition, brolucizumab has shown effectiveness in improving visual acuity in several studies [13–20]. However, the treatment for nAMD may respond differently in patients at different stages of the disease [21] as well as the treatment may differ in patients with diverse ethnicity and genetic make-up [4, 22, 23]. Thus, it is imperative to pool the efficacy data of brolucizumab from different populations belonging to various geographical locations and ethnicity. Unfortunately, the patient population in the HAWK and HARRIER studies did not include Indian patients. Thus, our study intended to evaluate the efficacy and non-inferiority of brolucizumab versus aflibercept in the Indian population.

Our study demonstrates the efficacy of brolucizumab to maintain the BCVA gains among a significant number of nAMD patients on a longer dosing interval over 48 weeks that were comparable to aflibercept therapy.
with shorter dosing intervals. The inter injection frequency data presented in Table 5 shows the achievement of injection free intervals up to 12 or more weeks in 71 out of 94 instances (75.5%), of re-injections after week 8, in the Brolucizumab group. The same data for Aflibercept was 62 eyes out of 180 (34.4%) achieving more than or equal to 12-week inter-injection interval and 101 out of 180 (56.1%) achieving more than or equal to 8-week inter-injection interval.

The measurement of BCVA changes can help evaluate the treatment’s efficacy in patients with nAMD [24]. Significant improvements were observed in the functional outcomes, i.e., BCVA gains. The logMAR BCVA in Indian patients in our study was significantly improved from 0.84 ± 0.32 at baseline to 0.70 ± 0.35 at week 48. The improvement was comparable to aflibercept demonstrating non-inferiority of brolucizumab as a treatment option for nAMD in Indian patients.

Further, anatomical outcomes assessed by OCT, such as CMT changes and the presence of retinal fluid (IRF, SRF, and SHRM), are important indicators of disease activity in nAMD patients [14, 23]. In our study, significant improvement was observed in CMT from baseline to week 48 in eyes treated with both the drugs. However, our results indicate that changes in CMT more significantly favoured brolucizumab over aflibercept. Furthermore, the retinal fluid resolution observed in patients treated with brolucizumab was better than aflibercept. The greater IRF resolution in brolucizumab treated patients was evident by weeks 24 and 28. At both time points, the majority of the brolucizumab patients were on a 12-week dosing interval compared to an 8-week dosing interval for aflibercept treated patients. Additionally, it has been shown that individuals with residual SRF at the end of the loading doses may have a negative impact on BCVA gains [15, 23]. Our results indicate fewer eyes treated with brolucizumab with SRF presence than aflibercept after the loading doses, i.e., at weeks 8, 12 and 16. This benefit was also maintained at weeks 44 and 48. These results corroborate previous studies [15, 17, 19, 20]. The SHRM resolution was comparable for both brolucizumab and aflibercept treated eyes. Any retinal fluid presence in the eyes suggests sub-optimal disease control [23, 25, 26]. Thus, improvement in retinal fluid resolution in brolucizumab treated eyes demonstrates an effective anti-VEGF therapy for nAMD Indian patients in clinical practice.

Furthermore, the number of injections required from week 12 to week 48 after 03 monthly doses were significantly lower for patients in the brolucizumab arm than the aflibercept arm. The average injection-free interval as computed by the probability of no injections between two intervals in the brolucizumab arm was also significantly higher compared to the aflibercept arm (Fig. 4). These results endorse the results of the study conducted by Dugel et al. (2017) with respect to the number of additional unscheduled treatments required. A significantly less proportion of patients required additional unscheduled treatments in the brolucizumab groups than the aflibercept group [27]. Also, similar results of improving the treatment interval were
Conclusions
In conclusion, significantly better BCVA gains, fluid resolution along with minimal ocular adverse events over 48 weeks were observed in eyes treated with brolucizumab monotherapy. The benefits observed with brolucizumab PRN therapy were non-inferior to aflibercept PRN therapy in patients with nAMD. The inter-injection interval achieved by Brolucizumab was higher than Aflibercept. This analysis suggests that brolucizumab could help alleviate the treatment and hospital visit burden associated with nAMD in Indian patients.

Acknowledgements
The authors would also like to acknowledge the medical writing and editorial support provided by CTQuest LLP, India and Dr. Shradhha Bhadada in the drafting and styling of this manuscript as per journal requirements.

Author contributions
SKM and PK planned and designed the study, SK and AJ performed the data collection, PK and SVK analysed and interpreted the data, SVK, PK and AS performed the clinical evaluation and multimodal imaging interpretation, SVK, PK and DU drafted the manuscript, revised, and edited the manuscript. All authors read and approved the final manuscript.

Funding
Nil

Availability of data and materials
The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by the local Institutional Ethics Committee (Approval no: 110/2020, dated 07 Dec 2020) of Army Hospital Research & Referral, Delhi Cantt. The trial was conducted compliant with the principles of the Declaration of Helsinki. Written informed consent was obtained from all the participants before recruitment in the study.

Consent for publication
The authors Sanjay Kumar Mishra, Pradeep Kumar, Srishti Khullar, Amrita Joshi, Alok Sati, Sonali Vinay Kumar & Deepesh Unni give their consent for publication. The consent for publication has been obtained from all participants before recruitment in the study.

Competing interests
The authors have no competing interest to declare.

Received: 12 April 2022 Accepted: 9 July 2022
Published online: 28 July 2022

References
1. Pugazhendhi A, Hubbell M, Jairam P, Ambati B. Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy. Int J Mol Sci. 2021;22(3):1170.
2. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16.
3. Sudhalkar A, Sethi V, Gogte P, Bondalapati S, Khodani M, Chhablani JK. Retrospective hospital-based analysis of age-related macular degeneration patterns in India: 5-year follow-up. Indian J Ophthalmol. 2015;63(12):899–904.
4. Xu X, Wu J, Yu X, Tang Y, Tang X, Shentu X. Regional differences in the global burden of age-related macular degeneration. BMC Public Health. 2020;20(1):410.
5. Krishnnaiah S, Das T, Nirmalan PK, Nutheti R, Shahanna BR, Rao GN, et al. Risk factors for age-related macular degeneration: findings from the Andhra Pradesh Eye Disease Study in South India. Invest Ophthalmol Vis Sci. 2005;46(12):4442–9.
6. Krishnan T, Ravindran RD, Murthy GVS, Vashist P, Fitzpatrick KE, Thulasiraj RD, et al. Prevalence of early and late age-related macular degeneration in India: the INDEYE study. Invest Ophthalmol Vis Sci. 2010;51(2):701–7.
7. Kulkarni SR, Aghashe SR, Khandekar RB, Deshpande MD. Prevalence and determinants of age-related macular degeneration in the 50 years and older population: a hospital based study in Maharashtra. India Indian J Ophthalmol. 2013;61(5):196–201.
8. Wong TY, Chatkavathy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(11):116–26.
9. Holekamp NM. Review of neovascular age-related macular degeneration treatment options. Am J Manag Care. 2019;25(Suppl 10):172–81.
10. Arepalli S, Kajeri PK. Pipeline therapies for neovascular age related macular degeneration. Int J Retina Vitr. 2021;7(1):55.
11. Ghanchi F, Bourne R, Downes SM, Gale R, Rennie C, Tapply I, et al. An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. Eye. 2022: https://doi.org/10.1038/s41433-021-01766-w.
12. Khanna S, Komati R, Eichenbaum DA, Hariprasad L, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4(1): e000398.
13. Markham A. Brolucizumab: first approval. Drugs. 2019;79(18):1997–2000.
14. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84.
15. Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89–99.
16. Bilgec A, Kojdujkin L, March de Ribot F, Vasavada V, Gonzalez-Cortes JH, Abukashabah A, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study. J Clin Med. 2021;10(13):2758.
17. Musial-Kopiejka M, Polanowska K, Dobrowolski D, Kyslik K, Wylegala E, Grabańek BO, et al. The effectiveness of brolucizumab and aflibercept in patients with neovascular age-related macular degeneration. Int J Environ Res Public Health. 2022;19(4):2303.
18. Singerman LJ, Weichselberger A, Sallstig P. OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD. Invest Ophthalmol Vis Sci. 2015;56(7):4801.
19. Chakrabory D, Matti A, Sheth JU, Borai S, Mondal S, Nandi K, et al. Brolucizumab in neovascular age-related macular degeneration – Indian real-world experience: The BRĂILLE study. Clin Ophthalmol. 2021;15:3787–95.
20. Murray JE, Gold AS, Latiff A, Murray TG. Brolucizumab: Evaluation of compassionate use of a complex anti-vegf therapy. Clin Ophthalmol. 2021;15:731–8.
21. Jaffe GJ, Kaiser PK, Thompson D, Gibson A, Saroj N, Vitti R, et al. Differential response to anti-vegf regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology. 2016;123(9):1856–64.
22. Lorés-Motta L, Riaz M, Grunin M, Corominas J, van Asten F, Pauper M, et al. Association of genetic variants with response to anti–vascular endothelial growth factor therapy in age-related macular degeneration. JAMA Ophthalmol. 2018;136(8):875–84.
23. Phan LT, Broadhead GK, Hong TH, Chang AA. Predictors of visual acuity after treatment of neovascular age-related macular degeneration – Current perspectives. Clin Ophthalmol. 2021;15:3351–67.
24. Gurung RL, FitzGerald LM, McComish BJ, Hewitt AW, Verma N, Burdon KP. Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal anti-vascular endothelial growth factor injections in clinical practice. BMJ Open Ophthalmol. 2021;6(1):e000749.
25. Broadhead GK, Hong T, Chang AA. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92(8):713–23.
26. Yeung L, Hsieh YT, Yang CH, Chen LJ, Chen SJ, Cheng CK, et al. Management of neovascular age-related macular degeneration: Taiwan expert consensus. J Formos Med Assoc. 2021;120(12):2061–71.
27. Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296–304.
28. Rave V, Sharma K, Wagner A, Kapoor K. Real-world analysis of brolucizumab in neovascular AMD. Invest Ophthalmol Vis Sci. 2021;62(8):431.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.